Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence

NCT04213118 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
TACE
Anlotinib

Interventions

DRUG: Anlotinib Hydrochloride
PROCEDURE: TACE

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Collaborators

[object Object]